Start Date
June 30, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
ILT-101 (Aldesleukin; IL-2)
Administration of Low-Dose Interleukin-2 (ILT-101) for two years
Treatment-Placebo Arm
Administration of Low-Dose Interleukin-2 (ILT-101) for one year, and then placebo for the second year.
Placebo Arm
Participants in this group will receive a placebo injection for two years.
Diabetes Research Institute, University of Miami Miller School of Medicine, Miami
Collaborators (1)
Diabetes Research Institute Foundation
OTHER
University of Florida
OTHER
University of California, San Francisco
OTHER
Jay S. Skyler
OTHER